News

In ARASEC, darolutamide plus ADT significantly improved survival and disease control versus ADT alone in mHSPC, complementing ARANOTE outcomes.

The FDA approved atezolizumab for the adjuvant treatment of muscle invasive bladder cancer with ctDNA molecular residual disease after cystectomy.

UGN-103 (mitomycin) for intravesical solution sustained disease control through 6 months in the UTOPIA trial in recurrent intermediate-risk LG-NMIBC.

Gedatolisib moves frontline in HR+/HER2– metastatic breast cancer, adding endocrine-sensitive patients and testing triplets vs ribociclib to boost PFS.

The FDA has granted suplexa, a non-engineered autologous cellular immunotherapy, fast track designation for patients with MSI-H colorectal cancer.

During a live event, Ronan J. Kelly, MD, MBA, and participants discussed how they use PD-1 inhibitors in patients with upper gastrointestinal cancers.

The phase 3 VOLGA trial showed perioperative durvalumab plus neoadjuvant enfortumab vedotin reduced the risk of death in muscle-invasive bladder cancer.

In an interview, Rawan Faramand, MD, discussed her research on cost-effectiveness of graft modification to prevent GVHD in hematopoietic cell transplant.

Mitomycin for intravesical solution demonstrated durable responses in 36-month follow-up data from the phase 3 ENVISION trial.

FDA approves an all-oral treatment for newly diagnosed acute myeloid leukemia, enhancing options for patients ineligible for intensive chemotherapy.

Sonrotoclax gains FDA approval as a promising treatment for relapsed mantle cell lymphoma, showcasing strong efficacy and safety in clinical trials.

Gene editing donor cells enabled less toxic targeted maintenance posttransplant; study was not continued for fiscal reasons.

The NEO-CYT trial began treating patients with melanoma in the perioperative setting, combining a novel agent with immune checkpoint inhibitor therapy.

Sexual activity, sexual desire, and physical function were improved by testosterone replacement therapy in men with hypogonadism post-prostatectomy.

Emiltatug ledadotin is a B7-H4–directed antibody-drug conjugate that has shown antitumor activity in adenoid cystic carcinoma and other solid tumors.

Andrzej Jakubowiak, MD, PhD, explains promising results for KRd maintenance and the potential of modifying the posttransplant maintenance paradigm in multiple myeloma.

The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan has elicited antitumor activity across subtypes of extrapulmonary neuroendocrine carcinomas.

INBRX-106 may act as a costimulatory agent and enhance pembrolizumab outcomes in head and neck squamous cell carcinoma.

During a live event, Caitlin Costello, MD, discussed the tools used to evaluate risk status for smoldering myeloma.

Mipletamig plus venetoclax and azacitidine delivers high remission rates and no CRS in early RAINIER trial, boosting hopes for unfit AML patients.

Blood MRD reveals hidden DLBCL after chemo; ALPHA3 trials off-the-shelf CD19 CAR T, boosting MRD clearance with low toxicity.

During a live event, Paolo Strati, MD and participants explore when to use CAR T in relapsed LBCL, how bispecific antibodies fit, and practical scan, access, and frontline CD19 strategy shifts.

The FDA has approvesd zenocutuzumab-zbco for previously treated NRG1 fusion–positive cholangiocarcinoma cholangiocarcinoma.

FDA fast tracks RPTR-1.201, a TCR bispecific immunotherapy for advanced triple-negative breast cancer, as RaPTR-101 tests safety and early efficacy.

The FDA previously granted RZ-001 both orphan drug designation and fast track designation for hepatocellular carcinoma.

The phase 1/2 data led to the phase 3 RASolute 302 trial which supported the FDA's allowance of early access to daraxonrasib in PDAC.

Intraperitoneal rintatolimod may boost outcomes with immunotherapies such as pembrolizumab in ovarian cancer.

Robert Coleman, MD, discusses how relacorilant plus nab‑paclitaxel boosts survival in platinum‑resistant ovarian cancer.